|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Human TCR Vbeta8|
|Storage buffer||PBS with 0.5% BSA, glycerol|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunohistochemistry (Frozen) (IHC (F))||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
|T-Cell Activation (TCA)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
TCR1750 targets TCR V beta 8b in FACS, IHC(F), IP, and TCA applications and shows reactivity with Human samples.
The TCR1750 immunogen is human TCR Vbeta8.
The ability of T cell receptors (TCR) to discriminate foreign from self-peptides presented by major histocompatibility complex (MHC) class II molecules is essential for an effective adaptive immune response. TCR recognition of self-peptides has been linked to autoimmune disease. Mutant self-peptides have been associated with tumors. Engagement of TCRs by a family of bacterial toxins know as superantigens has been responsible for toxic shock syndrome. Autoantibodies to V beta segments of T cell receptors have been isolated from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The autoantibodies block TH1-mediated inflammatory autodestructive reactions and are believed to be a method by which the immune system compensates for disease (ref5). T Cell and TCR Diversity Most human T cells express the TCR alpha-beta and either CD4 or CD8 molecule (single positive, SP). A small number of T cells lack both CD4 and CD8 (double negative, DN). Increased percentages of alpha-beta DN T cells have been identified in some autoimmune and immunodeficiency disorders. Gamma-delta T cells are primarily found within the epithelium. They show less TCR diversity and recognize antigens differently than alpha-beta T cells. Subsets of gamma-delta T cells have shown antitumor and immunoregulatory activity.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma.
TCR1750 was used in immunohistochemistry to study the change of Vbeta chain of T cell receptors during the leukemic phase of cutaneous T cell lymphoma
|Vonderheid EC,Boselli CM,Conroy M,Casaus L,Espinoza LC,Venkataramani P,Bigler RD,Hou JS||The Journal of investigative dermatology (124:651)||2005|
Immunological study on CD3 defective cutaneous T cell lymphoma cells from a patient with Sézary syndrome.
TCR1750 was used in immunohistochemistry to characterize T cell lymphoma cells from a Sezary syndrome patient
|Sano S,Matsui Y,Itami S,Yoshikawa K||Clinical and experimental immunology (113:190)||1998|
T-cell receptor repertoire expression in workers with occupational asthma due to platinum salt.
TCR1750 was used in flow cytometry to study the expression of TCR repertoire in patients suffered from asthma
|Raulf-Heimsoth M,Merget R,Rihs HP,Föhring M,Liebers V,Gellert B,Schultze-Werninghaus G,Baur X||The European respiratory journal (16:871)||2000|
Effects of HIV-1 peptides on T-cell receptor variable beta chain families.
TCR1750 was used in flow cytometry to study the role of HIV-1 peptides in the expansion and deletion of TCR Vbeta families
|Eick A,Larned J,Jason J||Human immunology (61:993)||2000|
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
TCR1750 was used in flow cytometry to develop and optimize a novel vaccination strategy
|Zaremba S,Barzaga E,Zhu M,Soares N,Tsang KY,Schlom J||Cancer research (57:4570)||1997|